Skip directly to page options Skip directly to A-Z link
Volume 23, Number 9—September 2017
Dispatch

Evaluation of 5 Commercially Available Zika Virus Immunoassays

David SafronetzComments to Author , Angela Sloan, Derek R. Stein, Emelissa Mendoza, Nicole Barairo, Charlene Ranadheera, Leanne Scharikow, Kimberly Holloway, Alyssia Robinson, Maya Traykova-Andonova, Kai Makowski, Kristina Dimitrova, Elizabeth Giles, Joanne Hiebert, Rhonda Mogk, Sharla Beddome, and Michael Drebot
Author affiliations: Public Health Agency of Canada, Winnipeg, Manitoba, Canada

Main Article

Table 3

Detection of IgM in RT-PCR–positive serum samples by using in-house and commercial Zika virus serologic assays*

Sample collection dpo In-house Zika virus diagnostic results
 DENV PRNT Commercial Zika virus serologic assays results
RT-PCR MAC-ELISA PRNT Euroimmun IgM Euroimmun IgG Novatec IgM Abcam IgM InBios IgM
0 Pos Neg ND ND Neg Neg Neg Neg Neg
2 Pos Neg ND ND Neg Neg Eq Neg Pos
5 Pos Neg ND ND Neg Neg Neg Neg Neg
7 Pos Pos ND ND Pos Pos Pos Pos Pos
3 Pos Neg ND ND Neg Neg Neg Neg Neg
2 Pos Neg ND ND Neg Neg Neg Neg Pos
2 Pos Pos ND ND Neg Neg Pos Neg Pos
3 Pos Neg ND ND Neg Neg Neg Neg Pos
3 Pos Neg ND ND Neg Neg Pos Neg PZ
2 Pos Neg ND ND Neg Neg Neg Neg Neg

*DENV, dengue virus; dpo, days postsymptom onset; Eq, equivalent; MAC-ELISA, IgM-capture ELISA; ND, not done; Neg, negative; Pos, positive; PRNT, plaque reduction neutralization test; PZ, possible Zika virus; RT-PCR, reverse transcription PCR.

Main Article

Page created: August 17, 2017
Page updated: August 17, 2017
Page reviewed: August 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external